Kiniksa Pharmaceuticals International, plc filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company incorporated in England and Wales. Form 8-K reports cover operating results and financial condition, ARCALYST portfolio execution, investor presentations, and executive appointments or consulting arrangements.
Proxy materials cover annual meeting matters, director elections, executive compensation, shareholder voting procedures, and board governance. The filing record also identifies the company’s Class A ordinary shares, Nasdaq Global Select Market listing, and recurring disclosures tied to its commercial ARCALYST franchise and cardiovascular-focused development portfolio.
Kiniksa Pharmaceuticals International, plc (KNSA) is identified as issuer in a notice listing a proposed sale, for Sanj K Patel's account, of 553,794 Class A ordinary shares, with an aggregate market value of $51,571,367.00. Charles Schwab & Co., Inc. is named as broker, and October 30, 2026 is listed as the approximate sale date.
The listed shares comprise 51,794 shares from a restricted stock lapse, 125,000 founders shares, and 377,000 shares from an employee stock-option exercise. The remarks state that options in the notice may be sold over various dates.
Kiniksa Pharmaceuticals International, plc (KNSA) lists a proposed sale of 103,585 Class A ordinary shares for officer Ross Moat, with an approximate sale date of October 30, 2026, through Charles Schwab & Co., Inc. The reported aggregate market value is $9,753,812.00. The listed share history includes 1,735 shares from a restricted stock lapse on April 1, 2026, 4,278 shares from a restricted stock lapse on September 1, 2026, and 97,572 shares from an employee stock option exercise on October 30, 2026, identified with broker payment for cashless exercise. The remarks state that sales may occur over various dates.
Kiniksa Pharmaceuticals International, plc (KNSA) is named as issuer in officer Michael R. Megna's Rule 144 notice covering the proposed sale of 47,540 Class A ordinary shares through Charles Schwab & Co., Inc. The listed aggregate market value is $4,559,561.00, with October 30, 2026 as the approximate sale date; the shares may be sold over various dates.
Kiniksa Pharmaceuticals International, plc lists an officer, John F. Paolini, in a notice to sell 96,000 Class A ordinary shares, with an aggregate market value of $8,930,275.00. Charles Schwab & Co., Inc. is listed as the broker. The securities are identified in connection with an employee stock option exercise and broker payment for a cashless exercise.
Kiniksa Pharmaceuticals International, plc (KNSA) reported third-quarter 2026 product revenue of $285.970 million, compared with $180.855 million in the same quarter of 2025, and net income of $47.345 million versus $18.435 million. For the nine months ended September 30, 2026, revenue was $743.836 million and net income was $95.369 million. ARCALYST sales generated substantially all product revenue; Kiniksa attributed the increase primarily to more patients on therapy.
Operating cash flow for the nine months ended September 30, 2026 was $144.941 million, compared with $84.091 million a year earlier. As of September 30, 2026, cash and cash equivalents were $81.660 million and short-term investments were $487.098 million. Management said existing cash, cash equivalents and short-term investments would fund operating expenses and capital expenditures for at least the next 12 months.
The pivotal Phase 3 KPL-387 trial in recurrent pericarditis had begun enrolling and dosing; Kiniksa expects data in the second half of 2027 and expects to begin commercialization in 2028 or 2029. It also expects to initiate a Phase 1 first-in-human trial of KPL-1161 by the end of 2026.
Kiniksa Pharmaceuticals International, plc reported third-quarter 2026 ARCALYST net product revenue of $286.0 million, representing approximately 58% year-over-year growth. Net income was $47.345 million, compared with $18.435 million; diluted earnings per ordinary share were $0.56 versus $0.23, and income from operations was $54.236 million versus $24.021 million. For the nine months ended September 30, 2026, revenue was $743.836 million and net income was $95.369 million.
Management raised its 2026 ARCALYST net product revenue outlook to $1.045 billion to $1.050 billion from a previous range of $980 million to $995 million. It expects 2026 research and development expenses of $160 million to $170 million and selling, general and administrative expenses of $270 million to $280 million, and expects its current operating plan to remain cash flow positive on an annual basis. At the end of the third quarter, approximately 23% of 14,000 annual multiple-recurrence patients were actively on ARCALYST; more than 5,450 prescribers had written ARCALYST prescriptions for recurrent pericarditis since launch. PASTORALE is enrolling up to approximately 85 patients. KPL-387 pivotal Phase 3 data are expected in the second half of 2027, while Kiniksa says it is on track to initiate a Phase 1 trial of KPL-1161 by the end of 2026.
Kiniksa Pharmaceuticals International, plc appointed Ross Moat President and Chief Operating Officer on October 17, 2026, effective immediately. He will continue to report to Sanj K. Patel, the company’s Chairman and Chief Executive Officer. Moat has served in varying capacities at Kiniksa since June 2019 and most recently served as EVP, Chief Operating Officer, overseeing commercial, clinical, regulatory and manufacturing operations.
Effective January 1, 2027, Moat’s annual base salary will increase to $700,000 from $650,000, and his annual target bonus will increase to 60% from 55%.
Kiniksa Pharmaceuticals International, plc (KNSA) reported insider equity activity by its chief financial officer, Mark Ragosa, on September 1, 2026. He received a grant of 7,800 Restricted Share Units and a share option for 31,150 Class A Ordinary Shares at an exercise price of $79.28 per share, with long-term vesting schedules. On the same date, several earlier RSU grants vested and were converted into Class A Ordinary Shares, and 4,404 shares were delivered or withheld for payment of exercise price or tax liability. No Rule 10b5‑1 trading plan is reported.
Kiniksa Pharmaceuticals International, plc (KNSA) reported multiple equity compensation and related transactions for Chairman & CEO Sanj K. Patel on September 1, 2026. He received 30,050 Restricted Share Units and a share option for 120,150 Class A Ordinary Shares at $79.28 per share, both vesting over time. On the same date, previously granted RSUs covering 31,318 shares were exercised into Class A Ordinary Shares, which were acquired indirectly by The Patel Family Irrevocable Trust of 2025, and 15,144 shares were delivered or withheld at $79.28 per share to pay the exercise price or tax liability. Following these and prior transactions, indirect holdings include 109,795 shares in The Marina 2016 Irrevocable Trust and 51,794 shares in The Anglia 2013 Revocable Trust.
Kiniksa Pharmaceuticals International, plc (KNSA) reported that chairman and CEO Sanj K. Patel received equity awards on September 1, 2026. He was granted 30,050 Restricted Share Units, each representing one Class A Ordinary Share, and 120,150 share options with an exercise price of $79.28 per share expiring on August 31, 2036. On the same date, several previously granted Restricted Share Units vested and were converted into Class A Ordinary Shares held indirectly through The Patel Family Irrevocable Trust of 2025, with 15,144 shares delivered or withheld to cover the exercise price or tax liability at $79.28 per share. Indirect holdings also include 109,795 Class A Ordinary Shares held by The Marina 2016 Irrevocable Trust and 51,794 Class A Ordinary Shares held by The Anglia 2013 Revocable Trust. No Rule 10b5-1 trading plan is reported for these transactions.